<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">
Log In

SmartTRAK Life Sciences News and Analysis Blog

3 min read

Personalized Arthroplasty: The Future of Total Joint Surgery?

By Nick Fitzpatrick on 1/26/23 10:22 AM

SmartTRAK interviews Dr. Pascal-André Vendittoli to learn more about the Personalized Arthroplasty Society and this year’s annual meeting.

Dr. Vendittoli explains the difference between mechanical and kinematic alignment, what he looks for in total joint computer-assisted surgery systems and why he thinks personalized arthroplasty is the future of joint surgery. To find out more, listen to the SmartTRAK interview with Dr. Vendittoli in the video below (14:56 min). A link to download the transcript of the complete interview is also provided below.
Continue Reading
3 min read

The Future of PEKK in Orthopedics: An Interview w/ Oxford Performance Materials' Scott Felice

By Nick Fitzpatrick on 1/23/23 10:18 AM

SmartTRAK interviews Oxford Performance Materials CEO Scott DeFelice to learn more about the company’s PEKK-based materials solutions in orthopedics.

In an interview with   SmartTRAK, Oxford Performance Materials’ (OPM) CEO Scott DeFelice explains the history of his company, the difference between PEKK, PEEK and titanium-based implants and the Company’s future plans in the orthopedic space.

To find out more, including OPM’s plan to expand into the custom trauma market and its planned release of an all-polymer total knee, just click on the following video to listen to the full interview. (29:13 min).  A link to download a transcript of the complete interview is also provided below.

Continue Reading
2 min read

Headwinds Persist: Q322 Arthroscopic Technologies Market Recap

By Andy Knapik on 1/20/23 11:01 AM

Headwinds persist for the Arthroscopic Technologies Market in Q322

With most of the major headwinds caused by COVID-19 in the rear-view mirror, the Arthroscopic Technologies (AT) Market showed growth in the third quarter with WW Arthroscopic Technologies revenues up +4.2% over Q321. The quarter saw a continued rise in procedural volumes globally that resulted in growth for the AT disposables market which trends with case volumes. On the capital side of the AT Market, capital spending and demand remained strong for items such as arthroscopic camera systems with new equipment purchases as well as an increasing need for replacement capital driving demand.

Among the many topics covered in detail in our comprehensive Q322 Arthroscopic Technologies Market Recap* are:

Continue Reading
2 min read

The Past, Present and Future of 3M Health Care

By Susan Paquette on 1/17/23 9:18 AM

With the recent announcement that 3M is spinning off its Health Care division, SmartTRAK looks back at the evolution of 3M Health Care, its businesses today, the entry into Advanced Wound Care (AWC) and potential new opportunities for the new Health Care business.

3M, a large, diversified company with annual sales of $35.4B in 2021 announced earlier this year plans to spin-off its Health Care business into a new public company. Today, 3M markets thousands of products through four business groups: Safety and Industrial, Transportation and Electronics, Health Care and Consumer. Post-spin-off, 3M will continue as a leading global material science innovator, while the new stand-alone business will seek to become a global diversified healthcare company focused on wound care, healthcare IT, oral care and biopharma filtration.

Download "The Past, Present and Future of 3M Health Care" Article
Among the many topics covered in this fascinating article are:

Continue Reading
2 min read

A Shifting Procedural Landscape: Q322 Spine Market Recap

By Courtney Sheedy on 1/12/23 9:52 AM

SmartTRAK reports that Q322 Spine Market performance drove a lack of consensus on operational performance metrics, while a shifting procedural landscape offered new product opportunities for small and mid-tier players, driving competitive pressure.

Among the many topics covered in detail in our comprehensive Q322 Spine Market Recap* are:

Continue Reading
2 min read

Neuromodulation Trends: SmartTRAK at NANS 2023

By Thomas Wallick on 1/10/23 9:00 AM

SmartTRAK takes a look back at Neuromodulation Trends in 2022 and looks forward to reporting on emerging trends at NANS 2023

Anne Staylor, SmartTRAK's Executive Editor VP & GM, Neuro Therapies, will again be attending and reporting on the North American Neuromodulation Society Annual Meeting (NANS), this year being held in Las Vegas, January 12-15th. If you would like to meet with Anne while at NANS, just click here.

Last year, Anne published a prescient article from the NANS 25th Annual Meeting titled "Neuromodulation Trends in 2022 and Beyond" in which she identified key trends from the meeting in Orlando and provided an outlook of what’s on the horizon for neuromodulation. This included trends in research and technology that will help shape the markets for spinal cord stimulation (SCS), deep brain stimulation (DBS) and peripheral nerve stimulation (PNS), advances in closed-loop therapies, improving care through digital solutions and driving growth through expanding indications.

To download and read the complete "Neuromodulation Trends in 2022 and Beyond" article, just click here.  

Continue Reading
2 min read

Continuing the Ascent: Q322 US Surgical Matrices Market Recap

By Doug Devens on 1/9/23 10:47 AM

Biosynthetic hernia matrices continue their ascent and Xenograft hernia matrices grow, thanks to TELA Bio.

As elective surgical procedures settle into pre-pandemic levels, the US Surgical Matrices Market resumed trends that had begun prior to Q322, gaining +2.4% YoY according to SmartTRAK Financial Dashboard. AbbVie* and Becton Dickinson* (BD) have been trading share positions in the last few quarters and now once again AbbVie has first place in the Q322 Surgical Matrices market despite of a -5.4% YoY decline, with BD In second place.

Among the many topics covered in detail in our comprehensive Q322 US Surgical Matrices Market Recap* are:

Continue Reading
2 min read

New Products and Easier Comps Drive US Growth: Q322 Trauma Market Recap

By Natasha Weeks on 1/3/23 9:30 AM

Despite declining OUS results, the US Trauma Market experienced healthy growth attributed to adoption of new products.

While OUS results declined in Q322 due to foreign currency headwinds and China’s value-based pricing, the US drove the overall market through product penetration and easier comps due to the Q321 COVID waves that impacted procedural volumes last year. Companies posted healthy US growth, attributing new products for driving growth, with plans for additional launches in Q4 and 2023.

Among the many topics covered in detail in our comprehensive Q322 Trauma Market Recap* are:

Continue Reading
2 min read

Wrestling with Issues and Headwinds: Q322 Neuromodulation Market Recap

By Anne Staylor on 12/29/22 9:30 AM

Growth in the SCS and DBS segments remained soft in Q322 as companies continue to wrestle with macro-environmental issues and currency headwinds

Neuromodulation continued to face a challenging macro environment in Q322 related to stubborn inflationary pressures, currency exchange headwinds and unpredictable surges in COVID affecting supply chains and healthcare staffing in certain geographies. However, some competitors reported seeing steady signs of improvement in the quarter and are looking to expanded indications and new technologies to help drive growth.

Among the many topics covered in detail in our comprehensive Q322 Neuromodulation Market Recap* are:

Continue Reading
2 min read

Trends in ADM Use from ASPS 2022

By Doug Devens on 12/20/22 9:30 AM

Surgeons are concerned about the cost of breast matrices in an increasingly restrictive environment, but alternatives may be on the horizon according to key discussions at the 2022 Plastic Surgery: The Meeting.

Breast matrices are used to cover breast implants in breast reconstruction and cosmetic breast surgeries. The matrices have become in effect standard of care in these surgeries, though they do not have FDA-approved indications for breast reconstruction or cosmetic breast surgeries. Moreover, the FDA has in recent years, issued warning letters and communications related to breast matrices. In 2015, the FDA issued warning letters reminding several companies that they did not ...

To read the complete "Trends in ADM Use from ASPS 2022" article by Doug Devens, SmartTRAK's Product Director/Sr. Analyst - Wound, in which  he shares observations from the ASPS sessions and the potential implications for the Breast Matrices Market, just click the following link.

Download the complete "Trends in ADM" Article

Continue Reading
  • There are no suggestions because the search field is empty.

Recent Articles